Biora Therapeutics, Inc. (BIOR)

Market Cap	6.40M
Revenue (ttm)	892,000
Net Income (ttm)	-31.54M
Shares Out	3.68M
EPS (ttm)	-10.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,026
Open	1.790
Previous Close	1.810
Day's Range	1.700 - 1.830
52-Week Range	1.700 - 19.900
Beta	1.28
Analysts	Strong Buy
Price Target	23.00 (+1,221.92%)
Earnings Date	Nov 14, 2024

About BIOR

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2020
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: BIOR
• Website: https://www.bioratherapeutics.com

Financial Performance

In 2023, Biora Therapeutics's revenue was $4,000, a decrease of -98.69% compared to the previous year's $305,000. Losses were -$124.12 million, 225.3% more than in 2022.

Analyst Forecast

According to one analyst, the rating for BIOR stock is "Strong Buy" and the 12-month stock price forecast is $23.0.

Price Target

$23.0

(1,221.92% upside)

Analyst Consensus: Strong Buy